Nivolumab

SAN FRANCISCO — Certain immune cell-related parameters appeared associated with efficacy of immune checkpoint inhibitors among patients with advanced or metastatic clear cell renal cell carcinoma, according to study results.

SAN FRANCISCO — Axitinib combined with nivolumab demonstrated encouraging efficacy among treatment-naive patients with metastatic renal cell carcinoma, according to study results presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — The combination of fam-trastuzumab deruxtecan-nxki and nivolumab demonstrated antitumor activity among patients with HER2-expressing urothelial carcinoma, according to results presented at ASCO Genitourinary Cancers Symposium.

First-line treatment with nivolumab in patients with advanced esophageal squamous cell carcinoma resulted in longer overall survival compared with chemotherapy treatment alone, according to research.

First-line nivolumab plus standard of care chemotherapy failed to prolong 1-year PFS among patients with metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

The benefit of immune checkpoint inhibitor therapy for hepatocellular carcinoma did not vary by underlying liver disease, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

A three-drug combination demonstrated activity for patients with microsatellite-stable, BRAF V600E-positive metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Nivolumab plus chemotherapy continued to confer clinically meaningful improvement in OS and PFS as first-line therapy for advanced gastric and esophageal cancers, according to a study presented at Gastrointestinal Cancers Symposium.

Neoadjuvant treatment with nivolumab and ipilimumab led to a high rate of pathologic complete response among patients with resectable microsatellite instability-high/mismatch repair deficient gastric cancers, study results showed.

Combination therapy with nivolumab plus ipilimumab conferred an OS benefit for patients with asymptomatic melanoma brain metastases, according to results of the open-label, phase 2 CheckMate 204 study published in The Lancet Oncology.